ICU Medical (NASDAQ:ICUI) Stock Price Expected to Rise, Piper Sandler Analyst Says

ICU Medical (NASDAQ:ICUI) had its price objective lifted by stock analysts at Piper Sandler from $163.00 to $195.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler’s price target suggests a potential upside of 6.74% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Raymond James Financial restated a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a report on Friday. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC increased their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, BTIG Research boosted their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Trading Up 9.8%

NASDAQ:ICUI traded up $16.32 on Friday, reaching $182.69. The company’s stock had a trading volume of 415,657 shares, compared to its average volume of 292,713. ICU Medical has a 1-year low of $107.00 and a 1-year high of $192.85. The business’s 50-day moving average price is $150.66 and its two-hundred day moving average price is $140.72. The firm has a market cap of $4.57 billion, a PE ratio of 99.11, a PEG ratio of 2.32 and a beta of 0.74. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same quarter last year, the firm posted $2.10 earnings per share. ICU Medical’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In related news, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hilton Head Capital Partners LLC bought a new stake in ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd increased its position in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the last quarter. Strs Ohio raised its stake in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of ICU Medical in the 4th quarter valued at approximately $120,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical News Roundup

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat estimates. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 consensus estimate and up from $2.10 a year earlier. Revenue of $547.88 million also exceeded expectations of $533.44 million. ICU Medical Q2 earnings report
• Positive Sentiment: Full-year guidance was raised above Wall Street expectations. ICU Medical now expects fiscal 2026 earnings of $8.60 to $9.00 per share, compared with the prior consensus estimate of $7.83. The improved outlook signals management expects continued earnings momentum. ICU Medical second-quarter results and guidance
• Positive Sentiment: Analysts responded by lifting their forecasts. Needham raised its price target from $165 to $187 and upgraded the stock to “Buy.” Other analysts also increased targets following the earnings beat and stronger guidance. Analyst forecasts following ICU Medical earnings
• Neutral Sentiment: Revenue growth remained modest. Second-quarter revenue increased only about 0.5% year over year, while the stock’s elevated valuation—approximately 100 times earnings—may limit additional upside despite the improved outlook. Needham’s new target also implies only limited near-term appreciation from recent trading levels.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.